Steven Hoerter Purchases Shares of CCCC
Steven Hoerter acquired 62,000 shares of CCCC, with shares trading around $4.40.
Key Points
- Steven Hoerter bought 62,000 shares of CCCC on June 24, 2026, with no specific price disclosed.
- On Saturday, CCCC shares traded near $4.40, with recent analyst ratings maintaining a 'buy' stance.
- Morgan Stanley increased its CCCC holdings by 90,738 shares, totaling 9,072,400 shares valued at $23.86 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Steven Hoerter made a notable move by purchasing 62,000 shares of CCCC on June 24, 2026. The transaction did not specify a purchase price or total value, but it reflects an insider's confidence in the company.
Other Institutional Activity in CCCC
Morgan Stanley grew its holdings by 90,738 shares, ending with 9,072,400 shares worth about $23.86 million. RA Capital Management, L.P. maintained its position with 8,000,000 shares valued at $21.04 million. Bain Capital Life Sciences Investors, LLC also held steady with 7,171,910 shares valued at $18.86 million. Lynx1 Capital Management LP reduced its stake by 99,231 shares, now holding 6,998,902 shares worth $18.41 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at $10.16 million.
C4 Therapeutics, Inc. Stock Up 14.3%
Shares of CCCC traded near $4.40 on Saturday. Despite the lack of detailed financial metrics, analysts have shown a positive outlook on the stock.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at C4 Therapeutics, Inc.
On June 24, 2026, several insiders, including Steven Hoerter, Laura Bessen, Stephen Fawell, Owen Hughes, Donna Roy Grogan, and Kenneth Carl Anderson, each purchased 62,000 shares, except Anderson who bought 1,070 shares at $2.11 per share. None of these transactions were planned under Rule 10b5-1 plans.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained a 'buy' rating on CCCC with a price target of $12. Barclays has also consistently maintained a 'buy' rating, with targets ranging from $5 to $10 in past assessments. The consensus among analysts remains optimistic, with a 'buy' recommendation.
Bottom Line
Steven Hoerter's recent purchase of CCCC shares highlights insider confidence, while institutional investors like Morgan Stanley are adjusting their positions. Analysts continue to favor the stock, maintaining 'buy' ratings with varied price targets. Investors should note that insider transactions are reported after the fact and may not reflect current positions.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.